These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25645908)

  • 41. Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice.
    Fefer P; Beigel R; Rosenberg N; Shechter M; Gannot S; Varon D; Savion N; Hod H; Matetzky S
    Platelets; 2015; 26(2):127-31. PubMed ID: 24617352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Platelets; 2015; 26(6):545-51. PubMed ID: 25167467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment.
    Kalantzi KI; Dimitriou AA; Goudevenos JA; Tselepis AD
    Platelets; 2012; 23(2):121-31. PubMed ID: 21806493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.
    Aradi D; Vorobcsuk A; Lenkey Z; Horváth IG; Komócsi A
    Platelets; 2010; 21(1):1-10. PubMed ID: 19929306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; Luca GD;
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):143-50. PubMed ID: 26868495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
    Oberhänsli M; Lehner C; Puricel S; Lehmann S; Togni M; Stauffer JC; Baeriswyl G; Goy JJ; Cook S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):587-92. PubMed ID: 23177487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
    Angiolillo DJ; Jakubowski JA; Ferreiro JL; Tello-Montoliu A; Rollini F; Franchi F; Ueno M; Darlington A; Desai B; Moser BA; Sugidachi A; Guzman LA; Bass TA
    J Am Coll Cardiol; 2014 Sep; 64(10):1005-14. PubMed ID: 25190236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
    van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
    Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
    [No Abstract]   [Full Text] [Related]  

  • 52. Diurnal variation in platelet inhibition by clopidogrel.
    Kozinski M; Bielis L; Wisniewska-Szmyt J; Boinska J; Stolarek W; Marciniak A; Kubica A; Grabczewska Z; Navarese EP; Andreotti F; Siller-Matula JM; Rosc D; Kubica J
    Platelets; 2011; 22(8):579-87. PubMed ID: 21627410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The H(2)-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y(12) inhibition in platelets.
    Schäfer A; Flierl U; Pförtsch S; Seydelmann N; Micka J; Bauersachs J
    Pharmacol Res; 2010 Oct; 62(4):352-6. PubMed ID: 20595015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
    Singla A; Antonino MJ; Bliden KP; Tantry US; Gurbel PA
    Am Heart J; 2009 Nov; 158(5):784.e1-6. PubMed ID: 19853698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction.
    Jeong YH; Cho JH; Kang MK; Koh JS; Kim IS; Park Y; Hwang SJ; Kwak CH; Hwang JY
    Thromb Res; 2010 Oct; 126(4):e334-8. PubMed ID: 20451242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
    Kreutz RP; Breall JA; Kreutz Y; Owens J; Lu D; Bolad I; von der Lohe E; Sinha A; Flockhart DA
    Thromb Res; 2012 Aug; 130(2):198-202. PubMed ID: 22459907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid.
    Verdoia M; Schaffer A; Pergolini P; Rolla R; Barbieri L; Bellomo G; Sinigaglia F; Marino P; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Jul; 66(1):35-40. PubMed ID: 25714593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.